Detalhe da pesquisa
1.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891379
2.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
N Engl J Med
; 385(24): 2219-2229, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34879448
3.
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.
J Am Acad Dermatol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554938
4.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Br J Dermatol
; 189(5): 540-552, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488811
5.
Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial.
J Am Acad Dermatol
; 89(5): 936-944, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172733
6.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36115523
7.
Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis.
J Drugs Dermatol
; 22(8): 766-772, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37556520
8.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Br J Dermatol
; 186(6): 942-954, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981829
9.
Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab.
J Drugs Dermatol
; 21(3): 235-240, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254755
10.
Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
J Drugs Dermatol
; 21(2): 162-171, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133113
11.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
JAMA
; 328(11): 1073-1084, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125472
12.
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
J Am Acad Dermatol
; 85(1): 71-78, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33744356
13.
A Retrospective Review of Patients' Response to Biologic Therapy for Psoriasis.
J Drugs Dermatol
; 20(4): 442-449, 2021 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852233
14.
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.
J Drugs Dermatol
; 20(8): 855-860, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34397205
15.
Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
J Am Acad Dermatol
; 82(2): 344-351, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175910
16.
Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.
J Am Acad Dermatol
; 82(6): 1314-1320, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32007513
17.
Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
J Drugs Dermatol
; 19(12): 1149-1155, 2020 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33346509
18.
Evaluation of Patient-Reported Outcomes With Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast.
J Drugs Dermatol
; 19(4): 378-383, 2020 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32272514
19.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
N Engl J Med
; 373(14): 1318-28, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26422722
20.
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
J Am Acad Dermatol
; 89(2): 345-347, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36521798